News and Announcements
OncoPac Global Clinical Study Receives Ethics Approval from Monash Health
- Published February 02, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) is a medical device company that focuses on localised treatments for patients with pancreatic and liver cancer. The Company are pleased to announce that they have been granted the Ethical Approval from the Monash Health for its OncoPac global clinical study program that is specialised for pancreatic cancer.
This study will provide a significant clinical study process to date. The Ethics Approval at Monash Health will also facilitate ethics approval for other participating study centres Australia-wide (excluding Western Australia); this in turn will help accelerate the patient recruitment process.
The success of this grant taking place at Monash Health comes after the Company filed its Ethics Committee (HREC) submission during November last year. Monash Health is the largest public health service in Melbourne, that has agreed to lead this Australian study. Monash provides health care services to over 1.5million people per year. This particular health care facility has also be named one of Victoria’s premier cancer facilities.
To date, OncoSil Medical has confirmed the participation of 12 centres for its global pancreatic clinical study program, along with currently being involved in further discussion with seven centres in the UK, Europe and Australia. The Company, will soon start adding new centres to its trail program in the coming months, along with commencing patient recruitment globally.
OnocSil Medical will update the market on the progress of the OncoPaC clinical study program in due course.
OncoSil Chief Executive Officer, Daniel Kenny commented:
“We are extremely pleased to have secured Ethics Approval for our global OncoPaC clinical study program in pancreatic cancer at Monash Health. Monash is a highly regarded cancer centre and is also the lead Australian centre for our clinical study program. With Ethics Approval granted at Monash, it now paves the way for the provision of ethics approvals across other Australian study centres, a pivotal requirement in the study program.”
To view the full announcement, please click here.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
